Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 in Advanced Solid Tumors with Hepatic Impairment
NCT02301104Phase 1Completed
- Sponsor
- Taiho Oncology
- Start
- Jan 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trifluridine + tipiracil in solid tumor (advanced stage) (4 arms), sponsored by Taiho Oncology. Primary endpoints: Pharmacokinetic parameters of FTD, FTY, and TPI and Safety monitoring including adverse events, vital signs, and laboratory assessments. Started Jan 2015; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02301104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02301104.